Literature DB >> 28078186

Soluble Receptor for Advanced Glycation End Products Improves Stromal Cell-Derived Factor-1 Activity in Model Diabetic Environments.

Melissa Przyborowski Olekson1, Renea A Faulknor1, Henry C Hsia2, Ann Marie Schmidt3, François Berthiaume1.   

Abstract

Objective: In diabetes, hyperglycemia causes the accumulation of advanced glycation end products (AGEs) that trigger reactive oxygen species (ROS) generation through binding the receptor for AGEs (RAGE). Because exogenous growth factors have had little success in enhancing chronic wound healing, we investigated whether hyperglycemia-induced AGEs interfere with cellular responses to extracellular signals. We used stromal cell-derived factor-1 (SDF-1), an angiogenic chemokine also known to promote stem cell recruitment in skin wounds. Approach: Human leukemia-60 (HL-60) cells and mouse peripheral blood mononuclear cells (PBMCs), which express the SDF-1 receptor CXCR-4, were incubated for 24 h in medium supplemented with 25 mM d-glucose. Soluble RAGE (sRAGE) was used to block RAGE activation. Response to SDF-1 was measured in cellular migration and ROS assays. A diabetic murine excisional wound model measured SDF-1 liposome and sRAGE activity in vivo.
Results: Hyperglycemia led to significant accumulation of AGEs, decreased SDF-1-directed migration, and elevated baseline ROS levels; it suppressed the ROS spike normally triggered by SDF-1. sRAGE decreased the ROS baseline and restored both the SDF-1-mediated spike and cell migration. Topically applied sRAGE alone promoted healing and enhanced the effect of exogenous SDF-1 on diabetic murine wounds. Innovation: While there is interest in using growth factors to improve wound healing, this strategy is largely ineffective in diabetic wounds. We show that sRAGE may restore signaling, thus potentiating the effect of exogenously applied growth factors.
Conclusion: Blocking RAGE with sRAGE restores SDF-1-mediated cellular responses in hyperglycemic environments and may potentiate the effectiveness of SDF-1 applied in vivo.

Entities:  

Keywords:  HL60 cells; advanced glycation end-products; cell migration; hyperglycemia; intracellular calcium; peripheral mononuclear white blood cells

Year:  2016        PMID: 28078186      PMCID: PMC5165672          DOI: 10.1089/wound.2015.0674

Source DB:  PubMed          Journal:  Adv Wound Care (New Rochelle)        ISSN: 2162-1918            Impact factor:   4.730


  31 in total

Review 1.  Advanced glycation end product receptor-mediated cellular dysfunction.

Authors:  Angelika Bierhaus; Per M Humpert; David M Stern; Bernd Arnold; Peter P Nawroth
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

Review 2.  Treating the chronic wound: A practical approach to the care of nonhealing wounds and wound care dressings.

Authors:  Margaret A Fonder; Gerald S Lazarus; David A Cowan; Barbara Aronson-Cook; Angela R Kohli; Adam J Mamelak
Journal:  J Am Acad Dermatol       Date:  2008-02       Impact factor: 11.527

Review 3.  Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer.

Authors:  William A Marston
Journal:  Expert Rev Med Devices       Date:  2004-09       Impact factor: 3.166

4.  Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice.

Authors:  M T Goova; J Li; T Kislinger; W Qu; Y Lu; L G Bucciarelli; S Nowygrod; B M Wolf; X Caliste; S F Yan; D M Stern; A M Schmidt
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

5.  Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial.

Authors:  A Veves; V Falanga; D G Armstrong; M L Sabolinski
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

6.  Activation of tubular epithelial cells in diabetic nephropathy.

Authors:  Michael Morcos; Ahmed A R Sayed; Angelika Bierhaus; Benito Yard; Rüdiger Waldherr; Wolfgang Merz; Ingrid Kloeting; Erwin Schleicher; Stefani Mentz; Randa F Abd el Baki; Hans Tritschler; Michael Kasper; Vedat Schwenger; Andreas Hamann; Klaus A Dugi; Anne-Marie Schmidt; David Stern; Reinhard Ziegler; Hans U Haering; Martin Andrassy; Fokko van der Woude; Peter P Nawroth
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

7.  Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways.

Authors:  Fatouma Touré; Günter Fritz; Qing Li; Vivek Rai; Gurdip Daffu; Yu Shan Zou; Rosa Rosario; Ravichandran Ramasamy; Arthur S Alberts; Shi Fang Yan; Ann Marie Schmidt
Journal:  Circ Res       Date:  2012-04-17       Impact factor: 17.367

8.  Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha.

Authors:  Katherine A Gallagher; Zhao-Jun Liu; Min Xiao; Haiying Chen; Lee J Goldstein; Donald G Buerk; April Nedeau; Stephen R Thom; Omaida C Velazquez
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 9.  Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response.

Authors:  Raphael Clynes; Bernhard Moser; Shi Fang Yan; Ravichandran Ramasamy; Kevan Herold; Ann Marie Schmidt
Journal:  Curr Mol Med       Date:  2007-12       Impact factor: 2.222

10.  A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers.

Authors:  Robert C Fang; Robert D Galiano
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.